Novel agents and new therapeutic approaches for treatment of multiple myeloma

doi:10.5662/wjm.v4.i2.73

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7842)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

480

WORD

353

HTML

4183

Figures (1-3)

288

Tables (1-4)

224

Sum=5528

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1053

Download

1261

Sum=2314

Jun 26, 2014 (publication date) through Nov 27, 2024

Times Cited of This Article

Times Cited (27)

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Methodol. Jun 26, 2014; 4(2): 73-90
Published online Jun 26, 2014. doi: 10.5662/wjm.v4.i2.73

Table 3 Combinations for relapsed/refractory patients

Regimen	Drugs	Ref.
MEL	High-dose melphalan	[54,55]
PDN	High-dose methylprednisolone	[56,57]
DEX	High-dose dexamethasone	[57]
VAD	Vincristine/ doxorubicin/prednisone	[58]
VMPC	Vincristine/melphalan/cyclophosphamide/prednisone	[58]
VBAP	Vincristine/carmustine/doxorubicin/prednisone	[58]
CEVAD	Doxorubicin/vincristine/dexamethasone/etoposide/cyclophosphamide	[59]
DCEP	Dexamethasone/cyclophosphamide/etoposide/cisplatin	[60]
DT-PACE	Cisplatin/doxorubicin/cyclophosphamide/etoposide	[61]
AlloSCT	Allogeneic transplant	[62,63]
ASCT	Second autologous transplant	[64,65]
THAL	Thalidomide monotherapy	[66,67]
TD	Thalidomide/dexamethasone	[68]
TC	Thalidomide/cyclophosphamide	[69]
TCD	Thalidomide/cyclophosphamide/dexamethasone	[70]
MPT	Melphalan/prednisone/thalidomide	[71]
MTD	Melphalan/thalidomide/dexamethasone	[72]
TAD	Thalidomide/pegylated liposomal doxorubicinxorubicin/dexamethasone	[73]
TAVD	Thalidomide/pegylated liposomal doxorubicinoxorubicin/vincristine/dexamethasone	[74]
TCED	Thalidomide/cyclophosphamide/etoposide/dexamethasone	[75]
BOR	Bortezomib monotherapy	[76-78]
VD	Bortezomib/dexametasone	[78]
VA	Bortezomib/pegylated liposomal doxorubicin	[79]
PAD	Bortezomib/low-dose dexamethasone/pegylated liposomal doxorubicin	[80]
VM	Bortezomib/melphalan	[81]
VCD	Bortezomib/low-dose cyclophosphamide/prednisone/	[82]
LEN	Lenalidomide monotherapy	[83]
RD	Lenalidomide/dexamethasone	[84-87]
RAD	Lenalidomide/doxorubicin/dexamethasone	[88,89]
REP	Lenalidomide/low-dose cyclophosphamide/prednisone	[90]
RCD	Lenalidomide/cyclophosphamide/dexamethasone	[91]
RAVD	Lenalidomide/pegylated liposomal doxorubicin/vincristine/dexamethasone	[1]
PATD	Bortezomib/ pegylated liposomal doxorubicin/thalidomide/dexamethasone	[92]
VMDT	Bortezomib/melphalan/dexamethasone/thalidomide	[93]
VMPT	Bortezomib/melphalan/prednisone/thalidomide	[94]
VTD	Bortezomib/thalidomide/dexamethasone	[95]
PAD	Bortezomib/pegylated liposomal doxorubicin/dexamethasone	[1]
VCTD	Bortezomib/cyclophosphamide/thalidomide/dexamethasone	[1]
VCRD	Bortezomib/cyclophosphamide/lenalidomide/dexamethasone	[1]
VRD	Bortezomib/lenalidomide/dexamethasone	[1]

Citation: Ria R, Reale A, Vacca A. Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol 2014; 4(2): 73-90
URL: https://www.wjgnet.com/2222-0682/full/v4/i2/73.htm
DOI: https://dx.doi.org/10.5662/wjm.v4.i2.73